Treating Inflammation through Resolution

SynAct Pharma – a clinical stage biotechnology company.

We focus our research and development on treatments with the ability to resolve rather the inhibit ongoing inflammatory processes in acute and chronic diseases.

Our lead compound, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key effector cells in the immune system thereby increasing the body’s ability to restore immune balance.

By focusing on early intervention in chronic inflammatory diseases we aim to reduce disease progression and limit the use of less well tolerated treatment options.

A parallel track to early intervention in inflammatory diseases is the potential of our compounds to modulate hyperinflammatory stages in viral diseases, with the ability to induce faster disease control and reduce the risk of severe organ dysfunction.

This science-driven strategy opens new possibilities across a wide spectrum of inflammatory conditions, where resolution therapy with our compounds could be a new standard of care treatment.